Ticagrelor tablets are contraindicated in patients with hypersensitivity (e.g., angioedema) to ticagrelor or any component of the product; in patients with a history of intracranial hemorrhage (ICH) because of a high risk of recurrent ICH in this population; in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage; and in patients with severe hepatic impairment.